|
|
►If you would like to make an appointment to learn more about Veltassa® please click the button to send an email to request a visit of our representative. |
|
Footnotes and references ADR, adverse drug reaction; GI, gastrointestinal *Hypomagnesaemia was mild-to-moderate, with no patient developing a serum magnesium level <1 mg/dL (0.4 mmol/L). Serum magnesium should be monitored for at least 1 month after initiating treatment, and magnesium supplementation considered in patients who develop low serum magnesium levels.1 †Since excessive doses of Veltassa® may result in hypokalemia, serum potassium levels should be monitored when initiated and up-titrated.1 1. Veltassa® EU SmPC 2024. 2. Pina IL, et al. Prog Cardiovasc Dis 2020;20:30163–8. 3. Bakris GL, et al. JAMA 2015;314(2):151–61. 4. Li L, et al. J Card Pharmacol Ther 2016;21(5):456–65. 5. Lesko LJ, et al. J Cardiovasc Pharmacol Ther 2017;22(5):434-446. |
|
|
